Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
Bingnan Zhang, MD, MBA
Advertisement
Articles by Bingnan Zhang, MD, MBA
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
Advertisement
Latest Updated Articles
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLCPublished: October 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
MCS-8, a Plant-Derived Drug, Reduces Prostate Cancer Incidence vs Placebo
2
Promises and Problems in Brain Cancer Therapy: What’s Hot Right Now?
3
Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population
4
Radiation ± Chemotherapy Shows Worse Short-Term QOL in Cervical Cancer
5
